Literature DB >> 9141073

Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate.

H S Ved1, M L Koenig, J R Dave, B P Doctor.   

Abstract

Huperzine a, a potential therapeutic agent for Alzheimer's disease, inhibits acetylcholinesterase in primary cultures derived from forebrain, hippocampus, cortex and cerebellum of embryonic rat brain. Glutamate induces cell death in cultures from all these brain regions. Maximum cell toxicity was observed in cerebellar cultures. Pretreatment of cell cultures with Huperzine A reduced cell toxicity, as evidenced by cytotoxicity assay and general morphology. Huperzine A pretreatment also reduced glutamate-induced calcium mobilization, but did not affect elevations in intraneuronal free Ca2+ ([Ca]i) caused by KCl or (-)Bay K 8644. The data suggest that Huperzine A could be a potent neuroprotective agent not only where cholinergic neurons are impaired, but also under conditions in which glutamatergic functions are compromised.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9141073     DOI: 10.1097/00001756-199703030-00029

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  19 in total

1.  The effects of huperzine A and IDRA 21 on visual recognition memory in young macaques.

Authors:  Ludise Malkova; Alan P Kozikowski; Karen Gale
Journal:  Neuropharmacology       Date:  2010-12-23       Impact factor: 5.250

Review 2.  Utility of nutraceutical products marketed for cognitive and memory enhancement.

Authors:  Graham J McDougall; Vonnette Austin-Wells; Teena Zimmerman
Journal:  J Holist Nurs       Date:  2005-12

3.  Huperzine A activates Wnt/β-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model.

Authors:  Chun-Yan Wang; Wei Zheng; Tao Wang; Jing-Wei Xie; Si-Ling Wang; Bao-Lu Zhao; Wei-Ping Teng; Zhan-You Wang
Journal:  Neuropsychopharmacology       Date:  2011-02-02       Impact factor: 7.853

4.  Intrathecal huperzine A increases thermal escape latency and decreases flinching behavior in the formalin test in rats.

Authors:  Paula Park; Steven Schachter; Tony Yaksh
Journal:  Neurosci Lett       Date:  2009-12-22       Impact factor: 3.046

Review 5.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

6.  A phase II trial of huperzine A in mild to moderate Alzheimer disease.

Authors:  M S Rafii; S Walsh; J T Little; K Behan; B Reynolds; C Ward; S Jin; R Thomas; P S Aisen
Journal:  Neurology       Date:  2011-04-19       Impact factor: 9.910

Review 7.  A Synopsis of Multitarget Potential Therapeutic Effects of Huperzine A in Diverse Pathologies-Emphasis on Alzheimer's Disease Pathogenesis.

Authors:  Mayuri Shukla; Prapimpun Wongchitrat; Piyarat Govitrapong
Journal:  Neurochem Res       Date:  2022-02-05       Impact factor: 3.996

Review 8.  Alternative medicine and Alzheimer disease.

Authors:  Brendan J Kelley; David S Knopman
Journal:  Neurologist       Date:  2008-09       Impact factor: 1.398

Review 9.  Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.

Authors:  Juan Wang; Hai-Yan Zhang; Xi-Can Tang
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

10.  Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis.

Authors:  Bai-Song Wang; Hao Wang; Zhao-Hui Wei; Yan-Yan Song; Lu Zhang; Hong-Zhuan Chen
Journal:  J Neural Transm (Vienna)       Date:  2009-02-17       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.